NIFTY 50 23344.75 ▲ (0.61%)
NIFTY NEXT 50 65106.15 ▲ (0.08%)
NIFTY 100 24048.8 ▲ (0.51%)
NIFTY MIDCAP 100 55106.2 ▲ (0.91%)
NIFTY SMALLCAP 100 17864.65 ▲ (1.09%)
NIFTY SMALLCAP 250 16841.4 ▲ (0.84%)
NIFTY MIDCAP SELECT 12356.5 ▲ (0.87%)
NIFTY TOTAL MARKET 12304.6 ▲ (0.6%)
NIFTY BANK 49350.8 ▲ (1.67%)
SENSEX 77073.44 ▲ (0.59%)
BSE BANKEX 56036.23 ▲ (2.03%)

Pfizer : Q4 2024 Financial Quarterly Report : YoY Sales Down 4.54 %, QoQ Up 1.23 %

May 18, 2024May 18, 2024| adminadmin| 0 Comments| 11:35 am
Image is loading
Categories:

Share the post "Pfizer : Q4 2024 Financial Quarterly Report : YoY Sales Down 4.54 %, QoQ Up 1.23 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company’s sales declined by -4.54 % over the year, substantial increase in net sales/revenue by 1.23 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 139.42 %. Marginal increase in other income during this quarter, up by 109.57%.
  • Profit over the Year and quarter: Significant improvement in profitability for Pfizer Ltd.,. Notable increase of 37.96 % in net profit Year to Year, Pfizer Ltd.,’s profitability increased by 37.61 % in this quarter.
  • EPS over the Year and quarter: EPS declined by -21.21 % Year to Year. EPS decreased by -17.66 % in previous quarter. Analysis needed for shareholder value.

The comprehensive analytics outlining the performance and outlook of Pfizer Ltd.,”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 572.64 Cr Rs. 539.97 Cr Rs. 546.63 Cr + 1.23 % -4.54 %
Expenses Rs. 390.77 Cr Rs. 387.42 Cr Rs. 357.2 Cr -7.8 % -8.59 %
Operating Profit Rs. 181.87 Cr Rs. 152.55 Cr Rs. 189.43 Cr + 24.18 % + 4.16 %
OPM % 31.76 % 28.25 % 34.65 % + 6.4 % + 2.89 %
Other Income Rs. 31.38 Cr Rs. 35.85 Cr Rs. 75.13 Cr + 109.57 % + 139.42 %
Interest Rs. 2.53 Cr Rs. 2.86 Cr Rs. 6.95 Cr + 143.01 % + 174.7 %
Depreciation Rs. 26.41 Cr Rs. 17.55 Cr Rs. 13.75 Cr -21.65 % -47.94 %
Profit before tax Rs. 184.31 Cr Rs. 167.99 Cr Rs. 243.86 Cr + 45.16 % + 32.31 %
Tax % 21.29 % 26.12 % 26.65 % + 0.53 % + 5.36 %
Net Profit Rs. 129.65 Cr Rs. 129.98 Cr Rs. 178.86 Cr + 37.61 % + 37.96 %
EPS in Rs Rs. 28.34 Rs. 27.12 Rs. 22.33 -17.66 % -21.21 %


Today, we’re looking at Pfizer Ltd.,’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -4.54 %. However, it did see a marginal increase of 1.23 % from the previous quarter. Expenses decreased slightly by -7.8 % quarter-on-quarter, aligning with the annual decline of -8.59 %. Operating profit, while up 4.16 % compared to last year, faced a quarter-on-quarter increase of 24.18 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.89 %, but an expansion of 6.4 % sequentially. Other income rose by 109.57 % compared to the last quarter, despite an annual growth of 139.42 %. Interest expenses surged remarkably by 143.01 % from the previous quarter, yet the year-over-year increase remains at a moderate 174.7 %. Depreciation costs fell by -21.65 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -47.94 %. Profit before tax grew annually by 32.31 % but saw an increase from the preceding quarter by 45.16 %.
Tax expenses as a percentage of profits increased slightly by 5.36 % compared to last year, with a more notable quarter-on-quarter increase of 0.53 %. Net profit rose by 37.96 % year-on-year but experienced a 37.61 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -21.21 % but a quarterly fall of -17.66 %. In summary, Pfizer Ltd.,’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 572.64 Cr Rs. 539.97 Cr Rs. 546.63 Cr + 1.23 % -4.54 %
Expenses Rs. 390.77 Cr Rs. 387.42 Cr Rs. 357.2 Cr -7.8 % -8.59 %
Operating Profit Rs. 181.87 Cr Rs. 152.55 Cr Rs. 189.43 Cr + 24.18 % + 4.16 %
Net Profit Rs. 129.65 Cr Rs. 129.98 Cr Rs. 178.86 Cr + 37.61 % + 37.96 %
EPS in Rs Rs. 28.34 Rs. 27.12 Rs. 22.33 -17.66 % -21.21 %


In reviewing Pfizer Ltd.,’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -4.54 % year-on-year, however, there was a minor increase of 1.23 % from the previous quarter. Expenses decreased by -8.59 % compared to the previous year, with a decrease of -7.8 % quarter-on-quarter. Operating Profit surged by 4.16 % annually, and saw a 24.18 % increase from the last quarter.
Net Profit showed yearly increase of 37.96 %, and experienced a 37.61 % increase from the previous quarter. Earnings Per Share (EPS) fell by -21.21 % annually, however dipped by -17.66 % compared to the last quarter. In essence, while Pfizer Ltd., exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Pfizer “]

Related Post